Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lapaquistat · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lapaquistat Acetate 100 mg QD | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD | EXPERIMENTAL | - |
| Atorvastatin 10 mg QD | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lapaquistat Acetate | DRUG | Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks |
| Placebo | DRUG | Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks |
| Lapaquistat acetate and atorvastatin | DRUG | Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks. |
| Atorvastatin | DRUG | Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks. |
Inclusion Criteria: * Female participants of childbearing potential cannot be been pregnant, lactating and are not planning on becoming pregnant and agrees to use acceptable forms of contraception throughout the course of this study. * Must have a mean low-density lipoprotein cholesterol values bet...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Lapaquistat is an investigational small molecule being developed for Type 2 Diabetes, Dyslipidemia, Hypercholesterolemia, and Hyperlipidemias. It is in Phase 3 clinical development for these cardiovascular conditions. The drug is not approved and remains under investigation.
Lapaquistat is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is an investigational small molecule in Phase 3 clinical development for cardiovascular indications including dyslipidemia and hypercholesterolemia.
Lapaquistat is in Phase 3 clinical development. It is an investigational drug and has not been approved. Seven clinical trials have been completed, with no active trials currently ongoing. The trials enrolled a total of 4,649 participants.
Lapaquistat has completed seven clinical trials, including NCT00143663, NCT00256178, NCT00487994, and NCT00864643. These Phase 3 and Phase 2 trials studied the drug's effects on cholesterol levels in patients with dyslipidemia and hypercholesterolemia, both alone and with statins like simvastatin and atorvastatin.
Lapaquistat is the same as Lapaquistat Acetate. Clinical trials refer to the drug as Lapaquistat Acetate, which is the active pharmaceutical ingredient being studied in patients with dyslipidemia and hypercholesterolemia.